Fenofibrate
- Generic Name
- Fenofibrate
- Brand Names
- Antara, Cholib, Fenoglide, Fenomax, Lipidil Supra, Lipofen, Tricor, Triglide
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21ClO4
- CAS Number
- 49562-28-9
- Unique Ingredient Identifier
- U202363UOS
- Background
Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.
Fenofibrate was granted FDA approval on 31 December 1993.
- Indication
Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.
- Associated Conditions
- Mixed Dyslipidemias, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Severe Fredrickson Type IV Hypertriglyceridemia, Severe Fredrickson Type V Hypertriglyceridemia
Cholesterol Drug Fenofibrate Shows Promise in Treating HPV-Related Cancers
• University Hospitals Seidman Cancer Center launches groundbreaking clinical trials to evaluate fenofibrate's potential in treating HPV-positive cervical and head and neck cancers.
• Pre-clinical studies reveal fenofibrate matches cisplatin's effectiveness against HPV+ cancers by restoring p53 tumor suppressor gene function and enhancing immune cell infiltration into tumors.
• The drug's excellent safety profile and targeted mechanism suggest potential for both therapeutic use and long-term prevention in high-risk individuals with HPV-related cancers.
Fenofibrate Adjunct Therapy Shows Promise in Mild to Moderate Ulcerative Colitis
• A clinical trial reveals that fenofibrate, when added to mesalamine, significantly improves clinical outcomes in patients with mild to moderate ulcerative colitis.
• The study demonstrates that fenofibrate reduces inflammatory markers such as NLRP3 and fecal calprotectin, while increasing SIRT1 and AMPK levels.
• Patients receiving fenofibrate in combination with mesalamine showed higher response and remission rates compared to those treated with mesalamine alone.
• The findings suggest fenofibrate as a safe and tolerable adjunct therapy, warranting further investigation for ulcerative colitis treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath